AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.